The decision is a setback for GLP-1 drugmakers, though it's not entirely surprising given the Trump administration’s focus on ...

Administration officials reversed a decision made during the Biden presidency that would have given millions of people access ...

The Centers for Medicare & Medicaid Services said on Friday it did not move forward with a proposal put forth by the Biden ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Trump officials reject Medicare coverage ...

As CMS maintains limits on GLP-1 coverage for weight loss, new efficacy data and shifting prescribing patterns point to sustained high demand across the drug class. Here are four updates: 1. Federal ...

However, a spokesperson for Novo Nordisk implied the Danish drugmaker plans to continue lobbying for expanded Medicare ...

Eli Lilly’s stock fell by 2.3% to close at 4:35 PM ET in after-hours trading, while Novo Nordisk’s American depositary receipts saw a decrease of 1.7%. This development came as a surprise to investors ...

Novo Nordisk joined the many pharmaceutical companies pushing back on government-negotiated drug pricing in the United States.

We had not assumed this proposed rule would pass, and we continue to think Novo and Lilly will gain Medicare obesity drug coverage via overlapping indications with time, such as Zepbound’s ...

The Centers for Medicare and Medicaid Services issued ... $620 and maintaining our DKK 640/$89 fair value estimate for Novo Nordisk. We had not assumed this proposed rule would pass, and we ...

The Centers for Medicare Medicaid Services (CMS) announced it will not proceed with a Biden administration proposal to expand ...

The U.S. announced an increase in Medicare Advantage payment rates for 2026, exceeding expectations and affecting insurer ...